Jula Inrig
About Jula Inrig
Jula Inrig serves as the Chief Medical Officer at Travere Therapeutics, a position she has held since 2022. With extensive experience in nephrology and clinical research, she has contributed to the development of therapies for rare kidney diseases and remains active in academia at both Duke University and UC Irvine.
Work at Travere Therapeutics
Jula Inrig has served as the Chief Medical Officer at Travere Therapeutics since 2022. In this role, she is responsible for overseeing the company's clinical development strategies and ensuring the successful execution of clinical trials. Her leadership contributes to the advancement of therapies aimed at treating rare diseases, particularly in the field of nephrology.
Education and Expertise
Jula Inrig holds a medical degree from Loma Linda University School of Medicine. She also studied at Duke University, where she earned a Master of Health Science in Clinical Research. Her extensive education underpins her expertise in nephrology and clinical drug development, positioning her as a knowledgeable leader in the field.
Background
Jula Inrig has a diverse professional background that includes significant roles in academia and clinical research. She has been an Associate Clinical Professor at UC Irvine School of Medicine since 2016 and has held various positions at Duke University Medical Center, including Adjunct Associate in Medicine since 2008. Her previous experience includes roles at UT Southwestern Medical Center and Duke Clinical Research Institute.
Achievements
Throughout her career, Jula Inrig has overseen the strategic planning and execution of over 45 clinical trials across 50 countries, enrolling more than 25,000 patients in nephrology indications during her time at QuintilesIMS. She has played a key role in the development of therapies for diabetic kidney disease, polycystic kidney disease, and lupus nephritis, contributing to advancements in treatment options for patients with rare diseases.
Clinical Research Contributions
Jula Inrig has made significant contributions to clinical research, particularly in nephrology. She has provided strategic support for global regulatory submissions and has collaborated with the FDA, EMA, and PMDA on various initiatives. Her work includes outlining the regulatory path for rare kidney diseases as part of the Kidney Health Initiative, demonstrating her commitment to advancing patient care in this area.